180 related articles for article (PubMed ID: 35793468)
21. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
Huang L; Wang R; Xie K; Zhang J; Tao F; Pi C; Feng Y; Gu H; Fang J
Breast Cancer Res Treat; 2022 Jan; 191(1):51-61. PubMed ID: 34657203
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models.
Tsumura R; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
Cancer Sci; 2019 Oct; 110(10):3296-3305. PubMed ID: 31348600
[TBL] [Abstract][Full Text] [Related]
24. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
Damelin M; Bankovich A; Bernstein J; Lucas J; Chen L; Williams S; Park A; Aguilar J; Ernstoff E; Charati M; Dushin R; Aujay M; Lee C; Ramoth H; Milton M; Hampl J; Lazetic S; Pulito V; Rosfjord E; Sun Y; King L; Barletta F; Betts A; Guffroy M; Falahatpisheh H; O'Donnell CJ; Stull R; Pysz M; Escarpe P; Liu D; Foord O; Gerber HP; Sapra P; Dylla SJ
Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077676
[TBL] [Abstract][Full Text] [Related]
25. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
26. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B
Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941
[TBL] [Abstract][Full Text] [Related]
28. EDB fibronectin and angiogenesis -- a novel mechanistic pathway.
Khan ZA; Chan BM; Uniyal S; Barbin YP; Farhangkhoee H; Chen S; Chakrabarti S
Angiogenesis; 2005; 8(3):183-96. PubMed ID: 16308732
[TBL] [Abstract][Full Text] [Related]
29. Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates.
Fang S; Brems BM; Olawode EO; Miller JT; Brooks TA; Tumey LN
Mol Pharm; 2022 Sep; 19(9):3228-3241. PubMed ID: 35904247
[TBL] [Abstract][Full Text] [Related]
30. Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S; Serwer L; DuPage A; Elkins K; Chauhan N; Ravn M; Buchanan F; Wang L; Krimm M; Wong K; Sagert J; Tipton K; Moore SJ; Huang Y; Jang A; Ureno E; Miller A; Patrick S; Duvur S; Liu S; Vasiljeva O; Li Y; Henriques T; Badagnani I; Jeffries S; Schleyer S; Leanna R; Krebber C; Viswanathan S; Desnoyers L; Terrett J; Belvin M; Morgan-Lappe S; Kavanaugh WM; Richardson J
Mol Cancer Ther; 2022 Aug; 21(8):1326-1336. PubMed ID: 35666803
[TBL] [Abstract][Full Text] [Related]
31. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.
Strop P; Tran TT; Dorywalska M; Delaria K; Dushin R; Wong OK; Ho WH; Zhou D; Wu A; Kraynov E; Aschenbrenner L; Han B; O'Donnell CJ; Pons J; Rajpal A; Shelton DL; Liu SH
Mol Cancer Ther; 2016 Nov; 15(11):2698-2708. PubMed ID: 27582525
[TBL] [Abstract][Full Text] [Related]
32. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma.
Yokota K; Serada S; Tsujii S; Toya K; Takahashi T; Matsunaga T; Fujimoto M; Uemura S; Namikawa T; Murakami I; Kobayashi S; Eguchi H; Doki Y; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Sep; 20(9):1713-1722. PubMed ID: 34224365
[TBL] [Abstract][Full Text] [Related]
33. A serologically assessed neo-epitope biomarker of cellular fibronectin degradation is related to pulmonary fibrosis.
Hansen AH; Breisnes HW; Prior TS; Hilberg O; Rasmussen DGK; Genovese F; Lukassen MV; Svensson B; Langholm LL; Manon-Jensen T; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB
Clin Biochem; 2023 Aug; 118():110599. PubMed ID: 37343745
[TBL] [Abstract][Full Text] [Related]
34. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW; Tanlimco SG; Hickson J; Fox M; Sho M; Durkin L; Uziel T; Powers R; Foster K; McGonigal T; Kumar S; Samayoa J; Zhang D; Palma JP; Mishra S; Hollenbaugh D; Gish K; Morgan-Lappe SE; Hsi ED; Chao DT
Cancer Res; 2018 Jul; 78(14):4059-4072. PubMed ID: 29764866
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer.
Tsumura R; Anzai T; Manabe S; Takashima H; Koga Y; Yasunaga M; Matsumura Y
Oncol Rep; 2021 Jan; 45(1):329-336. PubMed ID: 33200231
[TBL] [Abstract][Full Text] [Related]
38. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
39. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer.
Kanda M; Serada S; Hiramatsu K; Funauchi M; Obata K; Nakagawa S; Ohkawara T; Murata O; Fujimoto M; Chiwaki F; Sasaki H; Ueda Y; Kimura T; Naka T
Neoplasia; 2023 Jan; 35():100853. PubMed ID: 36413881
[TBL] [Abstract][Full Text] [Related]
40. TGF-β induces oncofetal fibronectin that, in turn, modulates TGF-β superfamily signaling in endothelial cells.
Ventura E; Weller M; Macnair W; Eschbach K; Beisel C; Cordazzo C; Claassen M; Zardi L; Burghardt I
J Cell Sci; 2018 Jan; 131(1):. PubMed ID: 29158223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
